文献速递免疫规划慢病防控与筛查

免疫抑制治疗中的成人炎症性肠病患者意外接种活疫苗

Inadvertent live vaccine administration in adult patients with inflammatory bowel disease on immunosuppressive therapy.
PubMed 文献 · Vaccine · 2024-09-07

该回顾性研究评估了35例接受免疫抑制治疗的炎症性肠病患者意外接种活疫苗后的情况,主要结局为接种后三个月内临床或播散性疾病发作。大多数患者使用抗肿瘤坏死因子(20例,57%),其次为硫唑嘌呤(12例,34%)和维得利珠单抗(3例,9%)。尽管活疫苗在免疫抑制治疗中属禁忌,但本研究中无患者报告任何感染。

要点

  • 35例接受免疫抑制治疗的炎症性肠病患者意外接种了活疫苗。
  • 主要结局为接种后三个月内的临床或播散性疾病发作。
  • 本研究中无患者报告任何感染。

核心结论

  • 尽管活疫苗在免疫抑制治疗中属禁忌,但本研究中无患者报告任何感染。

研究设计与样本

  • 回顾性研究,纳入35例接受免疫抑制治疗且意外接种活疫苗的炎症性肠病患者,主要结局为接种后三个月内的临床或播散性疾病发作。

主要发现

  • 22例接种麻疹、腮腺炎和水痘(MMR)疫苗,9例接种带状疱疹活疫苗,1例接种水痘疫苗(VAR),3例同时接种MMR和VAR。
  • 20例(57%)使用抗肿瘤坏死因子,12例(34%)使用硫唑嘌呤,3例(9%)使用维得利珠单抗。
  • 本研究中无患者报告任何感染。

局限性

  • 作者指出需进一步研究以探讨该人群接种活疫苗的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Live vaccines are contraindicated in patients on immunosuppressive therapy. We conducted a retrospective study evaluating the administration of a live vaccine in patients with IBD on immunosuppressive therapy. The primary outcome was to determine clinical or disseminated disease episodes within three months of vaccine administration in patients who inadvertently received a live vaccine. Thirty-five patients met the inclusion criteria. Twenty-two received the measles, mumps, and varicella (MMR) vaccine, nine received the live zoster vaccine, and one received the varicella vaccine (VAR). Three patients received both the MMR and VAR. The majority of our cohort (20, 57 %) were on anti-tumor necrosis factor, followed by azathioprine (12, 34 %) and vedolizumab (3, 9 %). Although live vaccines are contraindicated in patients on immunosuppressive therapy, none of the patients in this study reported any infections after inadvertent immunization. Further studies are required to address the safety and effectiveness of live vaccine administration in this population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ramirez OR, Farraye FA, Hayney MS, et al. Inadvertent live vaccine administration in adult patients with inflammatory bowel disease on immunosuppressive therapy. Vaccine. 2024. PMID: 39244424. doi:10.1016/j.vaccine.2024.126319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。